ALLMedicine™ Metastatic Breast Cancer Center

Jun 24th, 2022 - Background: Neurofibromatosis type 1 (NF1) is a genetic tumor predisposition syndrome (incidence of 1:3000), which results in the development of progressive tumor and non-tumor manifestations, the majority of which have no effective medical therap...

Jun 24th, 2022 - It is a phase III trial to explore the efficacy and safety of utidelone versus docetaxel in HER2-negative locally advanced or metastatic breast cancer.

Jun 24th, 2022 - Background Diffuse midline gliomas are the most aggressive brain tumors of childhood and young adults, with documented 2 year survival rates of <10%. These tumors are infiltrative midline high-grade gliomas. Treatment failure is due in part to the...

Jun 24th, 2022 - This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with exemestane plus everolimus in participants with estrogen receptor (ER)-positive, human epidermal growth f...

Jun 24th, 2022 - The safety and efficacy of pembrolizumab plus the investigator's choice of chemotherapy will be assessed compared to placebo plus the investigator's choice of chemotherapy in the treatment of chemotherapy-candidate hormone receptor-positive, human...

Oct 23rd, 2021 - ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer.|2021|Gennari A,André F,Barrios CH,Cortés J,de Azambuja E,|diagnosis,therapy,

Apr 8th, 2020 - Several new systemic therapy options have become available for patients with metastatic breast cancer, which have led to improvements in survival. In addition to patient and clinical factors, the treatment selection primarily depends on the tumor ...

Oct 17th, 2017 - Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update Summary.|2017|Van Poznak C,Somerfield MR,Moy B,|therapeutic use,drug therapy,secondary,drug therapy,pa...

May 25th, 2016 - To develop recommendations about endocrine therapy for women with hormone receptor (HR) -positive metastatic breast cancer (MBC). The American Society of Clinical Oncology convened an Expert Panel to conduct a systematic review of evidence from 20...

Sep 4th, 2014 - To identify optimal chemo- and targeted therapy for women with human epidermal growth factor 2 (HER2)- negative (or unknown) advanced breast cancer. A systematic review of randomized evidence (including systematic reviews and meta-analyses) from 1...

Jun 24th, 2022 - Background: Neurofibromatosis type 1 (NF1) is a genetic tumor predisposition syndrome (incidence of 1:3000), which results in the development of progressive tumor and non-tumor manifestations, the majority of which have no effective medical therap...

Jun 24th, 2022 - It is a phase III trial to explore the efficacy and safety of utidelone versus docetaxel in HER2-negative locally advanced or metastatic breast cancer.

Jun 24th, 2022 - Background Diffuse midline gliomas are the most aggressive brain tumors of childhood and young adults, with documented 2 year survival rates of <10%. These tumors are infiltrative midline high-grade gliomas. Treatment failure is due in part to the...

Jun 24th, 2022 - This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with exemestane plus everolimus in participants with estrogen receptor (ER)-positive, human epidermal growth f...

Jun 24th, 2022 - The safety and efficacy of pembrolizumab plus the investigator's choice of chemotherapy will be assessed compared to placebo plus the investigator's choice of chemotherapy in the treatment of chemotherapy-candidate hormone receptor-positive, human...

Jun 23rd, 2022 - Key clinical point: Etirinotecan pegol failed to prolong survival compared with chemotherapy in patients with metastatic breast cancer (BC) and stable pretreated brain metastases (BM). Major finding: The median overall survival (hazard ratio [HR].

Jun 23rd, 2022 - Key clinical point: Elacestrant significantly improved progression-free survival (PFS) compared with standard-of-care (SOC) endocrine monotherapy in previously treated patients with estrogen receptor-positive (ER+)/human epidermal growth factor re.

Jun 20th, 2022 - A study of elderly patients with HER2-positive/HR-negative metastatic breast cancer finds a significantly shorter median overall survival in actual clinical practice than younger counterparts. After 46 months of treatment, the survival rate was on.

Jun 20th, 2022 - A neighborhood analysis of socioeconomic status conducted in the Pittsburgh area found worse metastatic breast cancer survival outcomes among patients of low socioeconomic status. The findings suggest that race is not a relevant factor in outcomes.

Jun 16th, 2022 - Questions are now being asked about the comparator arm of a phase 3 trial in advanced breast cancer in which the investigational drug elacestrant (developed by Menarini/Radius Health) showed enough benefit for the companies to consider applying fo...